ESMO 2023 | ADC’s for the treatment of NSCLC

Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses the introduction of antibody-drug conjugates (ADCs) into the treatment of non-small cell lung cancer (NSCLC), as well as implementation strategy options for these therapies. Dr Besse elaborates on trials evaluating the efficacy of these treatments in patients with NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.